Background: The aim of this retrospective study is to investigate the therapeutic benefits and the bleeding risks of venovenous extracorporeal life support (VV-ECLS) when used for adult posttraumatic respiratory distress syndrome (posttraumatic ARDS). Materials and methods: Twenty adult trauma patients (median age: 38 years, median injury severity score: 35) treated with VV-ECLS in a level I trauma center between January 2004 and June 2013 were enrolled in this study. The indication of VV-ECLS for posttraumatic ARDS was refractory hypoxemia (P a O 2 /F i O 2 ratio ≤ 70 mmHg) under advanced mechanical ventilation. To minimize potential complications, a protocol-guided VV-ECLS was adopted.
Introduction
Acute respiratory distress syndrome (ARDS) is a potentially lethal problem in trauma patients [1, 2] . Based on the Berlin definition [3] , the typical presentation of posttraumatic ARDS is a hypoxemic status [an arterial oxygen tension (P a O 2 )/fraction of inspired oxygen (FiO 2 ) ratio ≤ 300 mmHg with a positive end-expiratory pressure (PEEP) ≥ 5 cmH 2 O] that is accompanied with bilateral pulmonary opacities, and occurs shortly after trauma. The common predisposing factors of posttraumatic ARDS are blunt thoracic injuries, traumatic shock requiring massive blood transfusion, and an injury severity score (ISS) ≥ 25 [2] . Similar to ARDS caused by nontraumatic etiologies, posttraumatic ARDS is primarily treated with mechanical ventilation. To reduce the injurious effects of cyclical inflation and deflation on the already injured lungs during positive pressure ventilation, lung-protective ventilation is preferred among ARDS patients, using low tidal-volumes (≤6 mL/kg/min) and optimal PEEPs to achieve an inspiratory plateau pressure (P plt ) ≤ 30 cmH 2 O [4, 5] . However increases in FiO 2, PEEP, and P plt may be unavoidable when an acceptable arterial oxygenation cannot be maintained. The hyperinflatedhyperoxic ventilation may exacerbate pulmonary shunting and induce a repeated mechanical-biological trauma [6] . This ventilator-induced lung injury may initiate a vicious cycle that leads to severe ARDS (P a O 2 /FiO 2 ratio ≤ 100 mmHg) with multiple organ dysfunctions [7] . Venovenous extracorporeal life support (VV-ECLS) may break this vicious cycle by conducting a prepulmonary blood gas exchange to share the workload with native lung, which enables physicians to continue lung-protective ventilation [8] . Nevertheless, because of its inherent thrombogenicity owing to the blood-surface interaction [9] , VV-ECLS requires systemic heparinization and involves a 40% risk of hemorrhage at intracranial, surgical, and cannulation sites [10] . This risk may increase when VV-ECLS is administrated to patients who have just sustained major trauma and damage-control interventions. These patients tend to have the trauma-induced coagulopathy (TIC) [11] and may be vulnerable to heparinization. To evaluate the therapeutic benefits and bleeding risks of VV-ECLS when used for posttraumatic ARDS, nine years of experience with this therapy was reviewed.
Materials and methods

Study population
From January 2004 to June 2013, a total of 561 patients received ECLS for hemodynamic (venoarterial mode; n = 437) or pulmonary (VV mode; n = 124) support at Chang Gung Memorial Hospital. Among the 124 patients, 20 adults had posttraumatic ARDS and were enrolled in this retrospective study. The institutional review board of the hospital approved the protocol (CGMF IRB no. 102-4437B) and waived the necessity of individual patient consent.
Therapeutic protocol: conventional mechanical ventilation
The definition of posttraumatic ARDS was based on the Berlin definition [3] . Conventional mechanical ventilation was used as the primary respiratory support for posttraumatic ARDS and a lung-protective strategy was adopted under paralytic sedation. The protocol of conventional mechanical ventilation for posttraumatic ARDS was demonstrated in our previous report [12] and showed in Additional file 1. When conventional mechanical ventilation alone was thought insufficient for an adequate arterial oxygenation (often a P a O 2 /FiO 2 ratio < 70 mmHg with a FiO 2 ≥ 0.8), VV-ECLS was administered. The exclusion criteria of VV-ECLS were (1) an uncontrolled hemorrhagic shock; (2) an identified acute heart failure; or (3) a severe traumatic brain injury. A whole body computed tomography was suggested to all candidates to exclude undetected internal hemorrhages before the administration of VV-ECLS.
Implantation of VV-ECLS
As reported previously [13] , we used the Capiox emergent bypass system (Terumo Inc., Tokyo, Japan) with a heparin-coated inner surface as our ECLS device. Since a double lumen catheter was not available during the period of study, two wire-wound polyurethane vascular cannulae (DLP Medtronic, Minneapolis, MN, USA; inflow: 19-23 French, outflow: 17-21 French) were used to established the femoral (in)-jugular (out) VV-ECLS via percutaneous cannulation. The ECLS gas flow rate was initially set high (10 L/min, pure oxygen), and the blood pump speed was gradually increased to achieve a pulse oximetry-detected oxyhemoglobin saturation (S p O 2 ) ≥ 90%. If necessary, a modest volume replacement (preferably packed red blood cell) was used to improve an unsteady ECLS blood flow. The positions of the cannula tips were confirmed with a chest-abdominal radiograph in order to prevent a substantial recirculation. Figure 1 illustrates our VV-ECLS protocol for posttraumatic ARDS. Anticoagulation, oxygenation, and ventilation were three highlighted points. Before implantation, the ECLS specialists must evaluate the risks and benefits of administering a fully heparinized (heparin-titrated) VV-ECLS to the trauma patient. Based on our experience of postcardiotomy ECLS [14] , we routinely administer the heparin-minimized ECLS to patients who require ECLS within 24 hours after major surgeries or trauma [15] , since these patients are at high risk for consumption coagulopathies. TIC is a consumption coagulopathy specific to trauma patients, and is defined as a hypocoagulable state [prothrombin time (PT)-international normalized ratio (INR) ≥ 1.2 or the activated partial thromboplastin time (aPTT) ≥ 35 seconds] presented soon after trauma [16, 17] . The active clotting time (ACT) and aPTT were checked as needed, at least every 6 hour in the first day of VV-ECLS. In heparin-titrated ECLS, the therapeutic range of the ACT/aPTT value was 160-180/40-55 seconds, and heparin was administered intravenously when the aPTT value dropped below 40 seconds. Patients on the heparinminimized ECLS received no exogenous heparinization. The heparin-minimized ECLS maintained a high blood flow rate (>3 L/min) and was switched to the heparintitrated mode after 48 hours to reduce the possibility of thromboembolism. To achieve acceptable oxygenation and to reduce the bleeding risk, hemaglobin and platelet count were also checked daily to maintain a level more than 10 g/dL and 80 billion/L, respectively. Coagulation factor transfusion was seldom needed in patients without hemorrhage. In patients with hemorrhages, withholding heparin plus blood transfusion (RBC: plasma: platelet about 1:1:3) was the first step to achieve hemostasis on ECLS. Endoscopic, angiographic or surgical hemostasis was launched with low threshold once the conservative treatment failed or was impossible to stablize the hemorrhage. When an obvious anisocoria (a diameter difference > 2 mm) was detected, a brain computed tomography was immediately performed to assess the possibility of ICHs. VV-ECLS was withdrawn (or rapidly weaned) after obtaining the family's permission when a major ICH was identified. The choice whether to perform a surgical decompression depended on the opinion of the consulting neurosurgeon.
Therapeutic Protocol of VV-ECLS in posttraumatic ARDS
The adequacy of oxygenation during VV-ECLS was checked by repeated arterial blood gas samplings, at least every 6 hours during the first day. With an improvement of S p O 2 , the lung-protective ventilation was continued with a decreased FiO 2 , respiratory rate, and P plt . However attempts to step-down the FiO 2 may be hindered by an unsatisfactory S p O 2 level in spite of a well-functioning VV-ECLS. A substantial recirculation of the outflow (oxygenated) blood of VV-ECLS was often found in this scenario and needed to be corrected quickly [18] . Figure 1 also outlines common methods of reducing the recirculation during VV-ECLS. After optimizing the oxygenation, it was critical to remove the excessive lung water with diuretics or continuous venovenous hemofiltration in order to improve the pulmonary compliance [19] . Weaning from the ECLS was tried once significant pulmonary improvements were shown. The pump flow was tapered to 2.0 L/min then the FiO 2 of the ECLS gas flow was turned to 0.21. Decannulation was performed after 4 to 6 hours if the patient remained stable. The weaning process would be stopped if (1) hemodynamic instability, or (2) a P a O 2 /FiO 2 ratio < 100 mmHg or P a CO 2 ≥ 60 mmHg under lung protective ventilation with a maximal FiO 2 of 0.6.
Statistical analysis
Statistical analyses were performed using SPSS for Windows (Version 15.0, SPSS, Inc., IL, USA). Because the dataset was small, nonparametric methods including the MannWhitney U or Wilcoxon signed ranks tests was used to conduct univariate comparisons of the independent or paired continuous variables. The Chi-square or Fisher's exact test was used to compare the categorical variables. The level of statistical significance was set at p < 0 .05.
Continuous variables with a p < 0.05 were dichotomized on the basis of cut-off values [14] . The cut-off values were determined by the receiver operating characteristic curve (ROC) analysis. These dichotomized risk factors were tested by the multivariate logistic regression analysis to identify independent predictors of in-hospital mortality and occurrence of major hemorrhages. 
Results
Demographics
Improvements of arterial gas exchange
A series of changes in P a O 2 /FiO 2 ratio during VV-ECLS between different patient groups was demonstrated in Table 3 . An improved oxygenation was showed in all patients soon after the administration of VV-ECLS. After testing by the Wilcoxon signed ranks test, the increase of P a O 2 /FiO 2 ratio was significant in survivors (p = 0.004), non-survivors (p = 0.03), patients with hemorrhages (p = 0.003), and patients without hemorrhages (p = 0.005). However, only the survivors showed a continuous increase in P a O 2 /FiO 2 ratio in the first day of VV-ECLS (p = 0.01).
The Incidence of Hemorrhaging during ECLS
Eleven patients (Cases 1-10 and Case 15 for just receiving surgery for empyema) fulfilled the criteria and received heparin-minimized VV-ECLS for 48 hours. Seven patients (six with TIC) had major hemorrhages during VV-ECLS, after a median ECLS duration of 12 (4-61) hours. All of the seven patients received heparin-minimized VV-ECLS as a prophylactic measure. The clinical presentations and management of the seven hemorrhagic complications are summarized in Table 4 . A series of changes in coagulation profiles during VV-ECLS between different patient groups was also demonstrated in Table 3 . To investigate the response of the patients' coagulation system to different ECLS strategies, aPTT data collected during the first day of VV-ECLS are presented as box plots in Figure 2 .
Discussion
This study aimed to investigate the therapeutic benefits and the safety of VV-ECLS when used for adult posttraumatic ARDS, since the ECLS-associated coagulopathy may induce severe consequences in trauma patients. As seen in previous reports [20, 21] and the current study, VV-ECLS is an efficient device to improve the blood gas exchange and may achieve a survival rate of more than 70% in adult patients with severe posttraumatic ARDS. The incidence of major hemorrhages during VV-ECLS is quite low in patients receiving VV-ECLS after several days of trauma, as seen in patients supported for non-traumatic ARDS [10] . According to a recent study reported by Ried et al. [20] , the incidence of major hemorrhages during extracorporeal lung support (n = 52; 26 used VV-ECLS) is only 4% (n = 2) in patients with a median trauma-to-ECLS time of 4.5 days. However, the therapeutic challenge here is administering VV-ECLS to patients at high risk for TIC. Despite being guided by a comprehensive protocol, the current study still yielded an incidence of major hemorrhages of 35% (n = 7) in 20 patients with a median trauma-to-ECLS time of 64 hours (2.7 days). The median trauma-to-ECLS time was only 10 hours in the group of hemorrhage. To explain the high incidence of major hemorrhages, we analyzed the changes of blood coagulability during VV-ECLS in order to evaluate the interaction between TIC and ECLS-associated coagulopathy. Since there is little literature information about this issue, the current report should provide valuable information to ECLS specialists who attempt to enroll patients that have just sustained major trauma or damage-control interventions.
As shown in Figure 2 , all patients experienced an extremely hypocoagulable state soon after being connected to an ECLS circuit. The suppression of blood coagulability decayed with time and almost disappeared after 12 hours in most of the patients. This phenomenon seemed to be compatible with the pharmacodynamics of heparin. Except the initial hypocoagulability, all patients showed a decreased platelet count after 24 hours of ECLS. This platelet consumption was also found in previous studies and could be explained by an increased volume of distribution and blood-surface interaction during extracorporeal circulation [9, 13] . Therefore we might suggest that the ECLS-associated coagulopathy was a profound hypocoagulable state induced by heparinization, hemodulition and platelet consumption [9] . This heparin-induced hypocoagulability may persist for 12 hours in adult patients with a relatively normal coagulability before VV-ECLS. From this viewpoint, reducing or even pharmacologically neutralizing the heparin content at the beginning of VV-ECLS should be helpful to attenuate the anticoagulant impact of ECLS.
In regards to the interaction between TIC and ECLSassociated coagulopathy, we had some indirect findings. As we were limited by the small number of cases, we failed to identify the correlation between TIC and the major hemorrhage during VV-ECLS, but we did find that the blood coagulability (both the intrinsic and external coagulation pathways) and the platelet counts were more suppressed in the hemorrhage group than in the non-hemorrhage group at the beginning of ECLS. Patients in the hemorrhage group also had more blood transfusions in the day before ECLS. Therefore, we may assume that these patients have a more severe TIC and are very sensitive to ECLS-associated coagulopathy, even to the heparin-minimized ECLS. The two coagulopathies may exert a synergistic effect strongly against blood coagulation and cause diffuse hemorrhages from the crushed solid organs and soft tissues. Despite there might be room for hemostasis with transfusion therapy alone, a proactive stance of surgical interventions should be taken toward major hemorrhages during ECLS. Not only because hemorrhages may reduce the efficacy of gas exchange on VV-ECLS by decreasing the pump flow rate and the amount of hemoglobin [22] , but also as the transfusion therapy itself may also worsen the existed pulmonary injury.
The limitations of this study are its retrospective design and the small number of cases involved. Further prospective and collaborative studies involving large populations and an integrated protocol of coagulation measurements (such as the thrombelastogram) are necessary to optimize the analysis of the therapeutic effects of VV-ECLS.
Conclusion
VV-ECLS is an effective respiratory support in adult posttraumatic ARDS. However, the risk of major hemorrhage during VV-ECLS may be significant in patients who have just sustained major trauma and have a packed or conservatively treated hemorrhage.
